Scientific Publications

Acazicolcept (ALPN-101)

Clinical publications

Feb 2021

Transplantation & Cellular Therapy

ALPN-101 (ICOSL vIgD Fc), a Dual Antagonist of the ICOS and CD28 Costimulatory Pathways, for Treatment of Steroid Refractory Acute GVHD ( aGVHD ): Case Report

Jan 2021

Clinical and Translational Science

First-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-101, a dual CD28/ICOS antagonist, in healthy adult subjects

Jun 2020

European Alliance of Associations for Rheumatology

A Double Blind, Placebo Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study of ALPN-101, a First-In-Class Dual ICOS/CD28 Antagonist, in Healthy Volunteers (HV)

Dec 2019

American Society of Hematology

An Open Label Study of ALPN-101, a First in Class Dual CD28/ICOS Antagonist, in Subjects with Steroid Resistant or Steroid Refractory Acute Graft Versus Host Disease (BALANCE)

Preclinical publications

May 2022

Association for Research in Vision and Ophthalmology

Systemic Administration of Acazicolcept(ALPN-101), a Dual ICOS/CD28 Antagonist, Suppresses Ocular Inflammation in Rat Experimental Autoimmune Uveitis

Jan 2022

Arthritis Research & Therapy

Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models

Oct 2020

Science Translational Medicine

ICOSL+ plasmacytoid dendritic cells as inducer of graft-versus-host disease, responsive to a dual ICOS/CD28 antagonist

Jan 2020

Crohn’s and Colitis Congress

ALPN-101, A First-In-Class Dual ICOS/CD28 Antagonist, Demonstrates Efficacy In Patient-Derived PBMC In Vitro And In an In Vivo T Cell Transfer Model Of Chronic Inflammatory Bowel Disease (IBD)

Nov 2019

American College of Rheumatology

ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector Mechanisms Associated with Sjögren’s Syndrome and Systemic Lupus Erythematosus

Nov 2019

American College of Rheumatology

ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector Mechanisms Underlying Rheumatoid and Psoriatic Arthritis

Apr 2019

Protein Engineering Summit

Protein Engineering by Directed Evolution to Derive ALPN-101, a Dual ICOS/CD28 Antagonist ICOSL Variant Ig Domain (vIgD)-Fc Fusion Protein for the Treatment of Inflammatory Diseases

Feb 2019

Transplantation & Cellular Therapy

ALPN-101, a Dual ICOS/CD28 Antagonist, Demonstrates Potent and Dose-Dependent Suppression of Graft vs. Host Disease (GvHD) in a Human/NSGTM Mouse Xenograft Model, with Activity Superior to CD28 or ICOS Single Pathway Antagonists

Dec 2018

American Society of Hematology

Therapeutic Candidate ALPN-101, a Dual ICOS/CD28 Antagonist, Potently Suppresses Human/NSG Mouse Xenograft Graft vs. Host Disease (GvHD) in a Dose Ranging Study and Reduces Disease Activity in a Mouse Model of Hemophagocytic Lymphohistiocytosis (HLH)

Oct 2018

American College of Rheumatology

ALPN-101, a Dual ICOS/CD28 Antagonist, Potently Suppresses Disease in Multiple Mouse Models of Autoimmunity

Oct 2018

American Neurological Society

Therapeutic Candidate ALPN-101, a Dual ICOS/CD28 Antagonist, Demonstrates In Vivo Efficacy in an Experimental Autoimmune Encephalomyelitis (EAE) Model

Dec 2017

American Society of Hematology

Novel Variant Ig Domain (vIgD) Proteins Generated Via Directed Evolution of IgSF Domains Have Therapeutic Efficacy in Animal Models of Graft Versus Host Disease

Davoceticept (ALPN-202)

Clinical publications

Jun 2022

American Society of Clinical Oncology

2560: Dose Escalation of Davoceticept, a Conditional CD28 Costimulator and Dual Checkpoint Inhibitor, in Advanced Malignancies (NEON-1)

Jun 2022

American Society of Clinical Oncology

TPS2683: Davoceticept (ALPN-202), a PD-L1-dependent CD28 Costimulator and Dual Checkpoint Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Malignancies (NEON-2)

Apr 2022

American Association for Cancer Research

Monotherapy dose escalation of davoceticept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1)

Nov 2021

Society for Immunotherapy of Cancer

A Study of ALPN-202, a PD-L1-dependent CD28 Costimulator and Dual Checkpoint Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Malignancies (NEON-2)

Jun 2021

American Society of Clinical Oncology

First in Human Dose Escalation of ALPN-202, A Conditional CD28 Costimulator and Dual Checkpoint Inhibitor, in Advanced Malignancies (NEON-1)

Apr 2021

American Association of Cancer Research

NEON-1: A First-in-Human Phase I Open-Label Study of ALPN-202, a Conditional CD28 Costimulatorand Dual Checkpoint Inhibitor, in Advanced Malignancies

Apr 2020

American Association of Cancer Research

NEON-1: A first in human phase I open label study of ALPN 202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies

Preclinical publications

Apr 2022

Nature Communications

The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity

Nov 2021

Society for Immunotherapy of Cancer

Development of a Clinical Ex Vivo Assay for the Assessment of Therapeutic CD28 Costimulatory Pathway Engagement

Jun 2020

American Association of Cancer Research

ALPN-202 Combines Checkpoint Inhibition with Conditional T Cell Costimulation to Overcome T Cell Suppression by M2c Macrophages and Improve the Durability of Engineered T Cell Anti-Tumor Responses

Mar 2020

United States and Canada Pathology Association

Development of Novel Monoclonal Antibodies for the Robust Detection of CD28, CD80, and CD86 by Immunohistochemistry in Human Tumors

Nov 2019

Society for the Immunotherapy of Cancer

ALPN-202, a Conditional CD28 Costimulator and Dual Checkpoint Inhibitor, Utilizes Multiple Mechanisms to Elicit Potent Anti-Tumor Immunity Superior to Checkpoint Blockade

Nov 2019

Society for the Immunotherapy of Cancer

ALPN-202, a Conditional CD28 Costimulator and Dual Checkpoint Inhibitor, Enhances the Activity of Multiple Standard of Care Modalities

ALPN-303

Jun 2022

European Alliance of Associations for Rheumatology

ALPN-303, an Engineered Dual BAFF/APRIL Antagonist, Potently Inhibits Pathogenic Autoantibodies in Preclinical Models, with Corresponding Pharmacodynamic Activity in Humans

Nov 2021

American College of Rheumatology

ALPN-303, an Enhanced, Potent Dual BAFF/APRIL Antagonist Engineered by Directed Evolution for the Treatment of Systemic Lupus Erythematosus (SLE) and Other B Cell-Related Diseases

Jun 2021

European Alliance of Associations for Rheumatology

ALPN-303, an Enhanced, Potent Dual BAFF/APRIL Antagonist Engineered by Directed Evolution for the Treatment of Systemic Lupus Erythematosus (SLE) and Other B Cell-Related Autoimmune Diseases

Jun 2020

European Alliance of Associations for Rheumatology

B Cell Modulatory Variant TNF Receptor Domains (vTDs) Identified by Directed Evolution to Inhibit BAFF and APRIL, Alone or Combined with Variant Ig Domains (vIgD™) that Inhibit T Cell Costimulation, for the Treatment of Systemic Lupus Erythematosus and Other Severe Autoimmune Diseases

Alpine Platform and Other Publications

Apr 2021

American Association of Cancer Research

Engineered Variant Domain Fusion Proteins Provide Checkpoint Inhibition and Tumor Antigen-Dependent CD28 Costimulation Resulting in Potent Anti-Tumor Immunity

Dec 2018

American Society of Hematology

“Switch” Transmembrane Immunomodulatory Proteins (TIPs) Consisting of High-Affinity PD-1 Extracellular Domains (PD-1 vIgDs) and Costimulatory Intracellular Domains Potently Enhance the Activity of TCR-Engineered T Cells